Search Results

Findings From OCTAMI Study Published

June 25, 2010—The OCTAMI (Optical Coherence Tomography [OCT] in Acute Myocardial Infarction) study of strut coverage and vessel wall response to zotarolimus-eluting stents (ZES) and bare-metal stents (BMS) implanted in patients with ST-segment elevation myocardial infarction (STEMI) was published in the Journal of the American College of Cardiology: Cardiovascular Interventions (2010;3:680–687).

OCTDESI Studies Boston Scientific's Jactax PES

July 20, 2010—Giulio Guagliumi, MD, et al published findings from OCTDESI (Optical Coherence Tomography Drug-Eluting Stent Investigation), a study of strut coverage and vessel wall response to Jactax (Boston Scientific Corporation, Natick, MA), a new-generation paclitaxel-eluting stent (PES) with an ultrathin biodegradable abluminal polymer.

Study Uses OCT and IVUS to Examine the In Vivo Mechanisms of Late DES Thrombosis

January 18, 2012—Giulio Guagliumi, MD, et al investigated the role of uncovered stent struts in late stent thrombosis after drug-eluting stent (DES) implantation with optical coherence tomography (OCT) and intravascular ultrasound (IVUS) and published their findings in the Journal of the American College of Cardiology: Cardiovascular Interventions (2012;5:12–20).

TRANSFORM-OCT Evaluates Strut Coverage and Neoatherosclerosis in Bioresorbable Versus Durable Polymer DES

November 2, 2016–Results from TRANSFORM-OCT, a prospective, randomized trial that used optical coherence tomography (OCT) to evaluate strut coverage and neoatherosclerosis found that bioresorbable polymer-based everolimus-eluting stents (BP-EESs) are comparable to durable conformable polymer-based zotoralimus-eluting stents (DP-ZESs).

St. Jude Medical's Ilumien Optis 3-D PCI Optimization System Approved in Europe

May 16, 2013—St.

St. Jude Medical Launches Optis Integrated System

September 15, 2014—St.